Lorlatinib Patent Expiration
Lorlatinib is Used for treating adult patients with metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive. It was first introduced by Pfizer Inc
Lorlatinib Patents
Given below is the list of patents protecting Lorlatinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Lorbrena | US11299500 | Crystalline form of lorlatinib free base hydrate | Oct 04, 2038 | Pfizer |
| Lorbrena | US10420749 | Crystalline form of lorlatinib free base | Jul 27, 2036 | Pfizer |
| Lorbrena | US11020376 | Crystalline form of lorlatinib free base | Jul 27, 2036 | Pfizer |
| Lorbrena | US8680111 | Macrocyclic derivatives for the treatment of diseases | Mar 05, 2033 | Pfizer |
Lorlatinib's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List